Clinical Trials Logo

Malignant Mesothelioma clinical trials

View clinical trials related to Malignant Mesothelioma.

Filter by:

NCT ID: NCT00227630 Completed - Clinical trials for Malignant Mesothelioma

Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Start date: July 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy before surgery may shrink the tumor so that it can be removed. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well giving pemetrexed disodium and cisplatin followed by surgery and radiation therapy works in treating patients with malignant pleural mesothelioma.

NCT ID: NCT00075699 Completed - Clinical trials for Malignant Mesothelioma

Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma

Start date: September 2003
Phase: Phase 3
Study type: Interventional

RATIONALE: Active symptom control may decrease chest pain, breathlessness, sweating, and general discomfort in patients with malignant pleural mesothelioma. It is not yet known if active symptom control is more effective with or without chemotherapy. PURPOSE: This randomized phase III trial is studying active symptom control and chemotherapy to see how well they work compared to active symptom control alone in treating patients with malignant pleural mesothelioma.

NCT ID: NCT00066651 Completed - Lung Cancer Clinical Trials

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

Start date: July 2003
Phase: Phase 1
Study type: Interventional

RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating advanced solid tumors. PURPOSE: This phase I trial is studying the side effects and best dose of immunotoxin therapy in treating patients with recurrent unresectable advanced solid tumors.

NCT ID: NCT00062283 Completed - Lung Cancer Clinical Trials

Alanosine in Treating Patients With Cancer

Start date: March 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy such as alanosine use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well alanosine works in treating patients with soft tissue sarcoma, sarcoma of the bone, mesothelioma, non-small cell lung cancer, or pancreatic cancer.

NCT ID: NCT00054002 Completed - Clinical trials for Malignant Mesothelioma

Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma

Start date: March 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer cells. Combining photodynamic therapy with surgery may be an effective treatment for malignant mesothelioma. PURPOSE: Phase II trial to study the effectiveness of combining photodynamic therapy with surgery in treating patients who have malignant mesothelioma.

NCT ID: NCT00053885 Completed - Clinical trials for Malignant Mesothelioma

PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma

Start date: July 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: PTK787/ZK 222584 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of PTK787/ZK 222584 in treating patients with unresectable malignant mesothelioma.

NCT ID: NCT00030745 Completed - Clinical trials for Malignant Mesothelioma

Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung

Start date: June 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have mesothelioma of the lung.

NCT ID: NCT00024076 Completed - Lung Cancer Clinical Trials

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Start date: May 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

NCT ID: NCT00020124 Completed - Lung Cancer Clinical Trials

Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs

Start date: June 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of inhaled doxorubicin in treating patients who have advanced solid tumors affecting the lungs.

NCT ID: NCT00019825 Completed - Lung Cancer Clinical Trials

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

Start date: October 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of decitabine in treating patients who have unresectable lung or esophageal cancer or malignant mesothelioma of the pleura.